A pilot study of JI-101, an inhibitor of VEGFR-2, PDGFR-尾, and EphB4 receptors, in combination with everolimus and as a single agent in an ovarian cancer expansion cohort

著录项

• 来源
  《Investigational New Drugs》 |2015年第6期|1217-1224|共8页
• 作者

  Theresa L. Werner; Mark L. Wade; Neeraj Agarwal; Kenneth Boucher; Jesal Patel; Aaron Luebke; Sunil Sharma;

  展开▼
• 作者单位

  Department of Medicine Oncology Division University of Utah Huntsman Cancer Institute">(1);

  Department of Medicine Oncology Division University of Utah School of Medicine Huntsman Cancer Institute">(3);

  Department of Medicine Oncology Division University of Utah Huntsman Cancer Institute">(1);

  Department of Medicine Oncology Division University of Utah Huntsman Cancer Institute">(1);

  Department of Oncologic Sciences University of Utah Huntsman Cancer Institute">(2);

  Department of Medicine Oncology Division University of Utah Huntsman Cancer Institute">(1);

  Department of Medicine Oncology Division University of Utah Huntsman Cancer Institute">(1);

  Department of Medicine Oncology Division University of Utah Huntsman Cancer Institute">(1);

  展开▼
• 收录信息
• 原文格式 PDF
• 正文语种 eng
• 中图分类
• 关键词

  JI-101; Everolimus; Ovarian cancer; Angiogenesis; VEGF;

  机译：JI-101;依维莫司;卵巢癌;血管生成;血管内皮生长因子;